TABLE 1.
Main clinical and biological characteristics of t(4;12)(q11‐13;p13) cohort
| Characteristics | n (%) |
|---|---|
| Total | 21 |
| Median age, years (range) | 78 (56–92) |
| Gender, male/female | 14 (67)/7 (33) |
| Median WBC, 109/L (range) | 18.2 (0.7–82.9) |
| Myeloid malignancies | |
| MDS with excess blasts a | 2/21 (10) |
| AML (FAB classification) | 19/21 (90) |
| AML 0 | 5/19 (26) |
| AML 1 | 5/19 (26) |
| AML 2 | 5/19 (26) |
| AML 4 | 1/19 (5) |
| Unspecified | 3/19 (15) |
| AML (WHO classification) | 19/21 (90) |
| AML with recurrent genetic abnormalities | |
| AML with mutated NPM1 | 1/19 (5) |
| AML with mutated RUNX1 b | 2/16 (25) |
| AML with myelodysplasia‐related changes | 12/19 (63) |
| Therapy‐related AML | 1/19 (5) |
| AML, NOS | 3/19 (5) |
| Cytological characteristics of AML | |
| Multilineage dysplasia | 10/19 (53) |
| Flow cytometry findings of AML blasts | |
| CD33+ | 15/15 (100) |
| CD7+ | 11/14 (79) |
| CD56+ | 7/11 (63) |
| CD7+ and/or CD56 + | 13/14 (93) |
| MPO+ | 3/13 (23) |
| Conventional karyotype | |
| Isolated t(4;12) | 10/21 (48) |
| One additional CA | 7/21 (33) |
| Complex karyotype | 4/21 (19) |
| FISH | |
| ETV6 rearrangement | 18/18 (100) |
| CHIC2 region rearrangement | 15/17 (88) |
Abbreviations: CA, chromosomal abnormality; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; NOS, not otherwise specified; WBC, white blood cell count.
a
One MDS with excess blasts (EB)‐1 (7%) and one with EB‐2 (11%).
b
Two other cases with RUNX1 mutations were included in AML with myelodysplasia‐related changes.